comparing car-t products for aggressive b-cell lymphoma: axi-cel versus tisa-cel
Published 5 months ago • 45 plays • Length 2:44Download video MP4
Download video MP3
Similar videos
-
1:39
out of specification anti-cd19 car t-cell products in aggressive b-cell lymphomas
-
2:14
comparing car t-cell toxicity in all and lymphoma
-
3:57
comparing bmt and car-t therapy: learnings for patient care and management
-
2:27
the potential of car t-cell therapy in combination with antibodies for the treatment of all
-
2:53
safety and efficacy of allogeneic car-t cell treatment
-
7:40
immunotherapy for aml and all: checkpoint inhibitors & car t-cells for b-cell all
-
12:15
car-t vs bispecific antibodies for lymphoma
-
1:46
next-generation car t-cell products for 2018
-
4:10
the challenges of car t-cell therapy for pediatric b-all
-
3:33
car t-cells for all
-
1:01
selecting costimulatory domains for car-t products
-
3:06
car-t and bites – which targets belong in clinical practice?
-
2:26
clinical data for cd19-directed car t-cell products in all
-
1:56
the state of car t-cell products today
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
6:40
car-t vs bispecifics: the best immune approach to replace asct
-
7:36
star t-cell therapy for r/r b-cell all
-
3:49
the limitations of immunotherapy with car t-cells
-
4:10
car t-cell therapy for all